Given the high attrition rates, substantial costs and slow pace of new drug discovery and
development, repurposing of'old'drugs to treat both common and rare diseases is …

Covalent drugs haveproved to be successful therapies for various indications, but largely
owing to safety concerns, they are rarely considered when initiating a target-directed drug …

Background Asciminib is an allosteric inhibitor that binds a myristoyl site of the BCR-ABL1
protein, locking BCR-ABL1 into an inactive conformation through a mechanism distinct from …

Purpose Addition of imatinib to intensive chemotherapy improved survival for children and
young adults with Philadelphia chromosome–positive acute lymphoblastic leukemia …

Background Resistance to tyrosine kinase inhibitors in patients with chronic myeloid
leukemia (CML) and Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph …

Epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) was
first recognized in 2004 as a distinct, clinically relevant molecular subset of lung cancer. The …

Deregulation of kinase activity has emerged as a major mechanism by which cancer cells
evade normal physiological constraints on growth and survival. To date, 11 kinase inhibitors …

The EML4 (echinoderm microtubule-associated protein-like 4)–ALK (anaplastic lymphoma
kinase) fusion-type tyrosine kinase is an oncoprotein found in 4 to 5% of non–small-cell lung …

The development and clinical application of inhibitors that target the epidermal growth factor
receptor (EGFR) provide important insights for new lung cancer therapies, as well as for the …

Recent studies suggest that thousands of genes may contribute to breast cancer
pathophysiologies when deregulated by genomic or epigenomic events. Here, we describe …